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Myeloperoxidase (MPO) and paraoxonase 1 (PON1) are high-density lipoprotein–associated (HDL-associ-
ated) proteins mechanistically linked to inflammation, oxidant stress, and atherosclerosis. MPO is a source 
of ROS during inflammation and can oxidize apolipoprotein A1 (APOA1) of HDL, impairing its atheropro-
tective functions. In contrast, PON1 fosters systemic antioxidant effects and promotes some of the atheropro-
tective properties attributed to HDL. Here, we demonstrate that MPO, PON1, and HDL bind to one another, 
forming a ternary complex, wherein PON1 partially inhibits MPO activity, while MPO inactivates PON1. 
MPO oxidizes PON1 on tyrosine 71 (Tyr71), a modified residue found in human atheroma that is critical for 
HDL binding and PON1 function. Acute inflammation model studies with transgenic and knockout mice for 
either PON1 or MPO confirmed that MPO and PON1 reciprocally modulate each other’s function in vivo. 
Further structure and function studies identified critical contact sites between APOA1 within HDL, PON1, 
and MPO, and proteomics studies of HDL recovered from acute coronary syndrome (ACS) subjects revealed 
enhanced chlorotyrosine content, site-specific PON1 methionine oxidation, and reduced PON1 activity. HDL 
thus serves as a scaffold upon which MPO and PON1 interact during inflammation, whereupon PON1 bind-
ing partially inhibits MPO activity, and MPO promotes site-specific oxidative modification and impairment 
of PON1 and APOA1 function.
Introduction
Cholesterol efflux activity and reverse cholesterol transport are 
regarded as the classic functions of high-density lipoprotein 
(HDL). Yet increasing evidence shows that additional cardiopro-
tective antioxidant and antiinflammatory functions of HDL exist 
(1, 2). Isolated HDL can reduce LDL-associated cholesteryl ester 
hydroperoxides, fatty acid hydroperoxides, and certain oxidized 
phosphatidylcholine molecular species (3). Moreover, HDL facil-
itates numerous antiinflammatory activities (4–7). Interestingly, 
reconstituted particles containing apolipoprotein A1 (APOA1), 
the major structural protein within HDL, can recapitulate some 
but not all of these activities (6–8). Thus, the antiinflammatory 
and antioxidant activities of HDL are thought to be mediated in 
part by both APOA1 within the core lipoprotein particle and an 
assortment of HDL-associated proteins.
Early proteomics studies of HDL provided the first glimpse into 
the complexity of the HDL-associated proteome, revealing HDL as 
a highly heterogeneous array of distinct particles that are equipped 
with a broad assortment of HDL-associated proteins, including 
not only previously recognized exchangeable apolipoproteins, 
but also numerous additional proteins involved in hemostasis, 
thrombosis, the immune and complement systems, growth fac-
tors, receptors, and hormone-associated proteins (9, 10). Subse-
quent studies both replicated these findings and extended them by 
suggesting that the composition of HDL-associated proteins may 
differ between subjects having clinically significant cardiovascular 
disease compared with healthy controls (11–13). This raises the 
possibility that alterations in HDL function may occur through 
changes in HDL-associated proteins. Indeed, the contemporary 
view holds that distinct HDL particle subpopulations exist, which 
are composed of unique clusters of specific HDL-associated pro-
teins that foster specific biological functions (12). For example, 
HDL particles enriched in paraoxonase 1 (PON1), an atheroprotec-
tive protein (14), have been linked to the antioxidative, antiinflam-
matory, and lipid cargo–carrying functions of HDL (7, 12, 15). An 
esterase/lipolactonase with unclear substrate(s) in vivo, PON1 has 
been shown to help HDL prevent the accumulation of lipid perox-
ides in oxidized LDL, inactivate bioactive oxidized phospholipids, 
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stimulate HDL-mediated eNOS-dependent NO production, and 
enhance cholesterol efflux from cholesterol-laden macrophages 
(7, 16–18). The participation of PON1 in HDL-related benefi-
cial functions extends to in vivo studies as well, since PON1 KO 
mice show enhanced susceptibility for developing atherosclerosis 
(19) and, conversely, Pon1 transgenic (Tg) mice demonstrate both 
protection from the development of atherosclerosis and reduced 
systemic measures of oxidation (20). Moreover, recent human 
studies show a striking correlation between multiple systemic 
measures of oxidant stress and serum PON1 activity measures 
(15), and reduced systemic PON1 activity heralds increased pro-
spective risks for major adverse cardiac events in subjects (15, 21, 
22). PON1 has thus emerged as an important mediator of many 
antiinflammatory, antioxidant, and atheroprotective activities of 
HDL. A role for an HDL-associated protein in modulating PON1 
activity levels within a distinct HDL particle subpopulation has 
not yet been reported.
Myeloperoxidase (MPO) is a leukocyte-derived heme protein 
that, like PON1, both binds to HDL and is mechanistically linked 
to oxidant stress and atherosclerosis (23–27). While typically 
found at very low levels within the plasma of healthy individu-
als, substantially elevated levels may be observed in the plasma 
or serum of those with acute coronary syndromes (ACS) and at 
risk for major adverse cardiac events (28). An enzymatic source 
of diffusible oxidant species, MPO promotes protein and lipid 
oxidation at sites of inflammation, including within the athero-
sclerotic plaque–laden artery where the enzyme is enriched and 
catalytically active (24, 29–32). Studies using neutrophils (PMN) 
isolated from subjects with MPO deficiency (PMNMPO–) reveal that 
MPO is also a major enzymatic catalyst for the initiation of lipid 
peroxidation within serum or plasma (33), and studies employing 
MPO KO mice confirm that the leukocyte enzyme plays a domi-
nant role in lipid peroxidation and eicosanoid formation at sites 
of acute inflammation (34). When released from activated leuko-
cytes, MPO within both the circulation and within human athero-
sclerotic plaque binds to HDL, targeting the particle for oxidative 
modification and functional inactivation (6, 23, 35). Site-specific 
oxidation of APOA1 of HDL by MPO has been linked to impair-
ment in cholesterol efflux and LCAT-activating activities of the 
lipoprotein, inhibition in antiinflammatory and antiapoptotic 
properties of HDL, and acquisition of proinflammatory gain-of-
function activities (6, 23).
The processes that regulate MPO activity in vivo are unclear. 
Our current understanding is that the availability of MPO is 
regulated predominantly by the extent of leukocyte activation 
and granule content secretion, and catalytic activity of released 
MPO is governed in large part by hydrogen peroxide substrate 
availability. Whether MPO activity is further modulated by 
interaction with additional proteins, such as after binding to 
the HDL particle or a specific HDL-associated protein, is not 
known. Given the numerous mechanistic and opposing links 
between MPO and PON1 with systemic measures of oxidant 
stress, inflammation, and atherosclerotic risk, we hypothesized 
that these two HDL-associated proteins may functionally inter-
act and inhibit each other’s catalytic activity either on HDL or 
outside of their association with HDL.
Results
MPO and PON1 bind to one another and reciprocally inhibit each 
other’s activity. To test the hypothesis that HDL, PON1, and MPO 
modulate each other’s activity, we initially examined whether 
immunoprecipitation studies were consistent with a poten-
tial complex being formed between HDL, MPO, and PON1 in 
plasma. As expected, antibodies against APOA1 pulled down both 
MPO and PON1 from plasma (Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI67478DS1). Importantly, cross immunoprecipitation stud-
ies in plasma with antibodies against either MPO or PON1 were 
also consistent with ternary complex formation involving HDL 
(APOA1), MPO, and PON1, since immunoprecipitation with anti-
bodies against either MPO or PON1 similarly pulled down the 
other 2 components (Supplemental Figure 1). To more fully assess 
the strength of the interactions between each component of a pre-
sumptive HDL-MPO-PON1 complex, plasmon resonance spec-
troscopy was performed to evaluate binding interactions between 
each of the components. Remarkably, HDL, MPO, and PON1 each 
bound to one another with high affinity, showing KD values in the 
low nanomolar-to-picomolar range, depending on the interaction 
examined (Supplemental Figure 2).
PON1 in plasma is present on a subset of HDL particles (esti-
mated at approximately 1 of 8–10 HDL particles) (36). And 
MPO is significantly less abundant than either PON1 or HDL in 
plasma. Western blot analyses with MPO antibodies following 
immunoprecipitation with either PON1 or APOA1 reveal that the 
vast majority of MPO in plasma is bound to HDL and PON1, as 
nominal detectable MPO remains in the supernatant following 
immunoprecipitation with antibodies against APOA1 and PON1 
(not shown). The above binding studies suggest that MPO, when 
present within plasma or serum or within other bodily tissues or 
fluids, may interact with APOA1 and PON1 in a subset of HDL 
particles. The ability of MPO to oxidize APOA1 and alter HDL 
function is well known (6, 23). Whether interactions between MPO 
and PON1 might alter the function of each of these HDL-asso-
ciated proteins, however, is unclear. We therefore next examined 
whether MPO activity (using varying levels of H2O2) impacted 
PON1 activity within a complex matrix-like serum. Physiologi-
cal levels of HDL (1 mg protein/ml) and PON1 (100 μg/ml) were 
added to lipoprotein-deficient serum from a healthy volunteer in 
which the MPO levels measured were nominal (<50 picomolar). In 
the absence of additional MPO, increasing amounts of the MPO 
substrate H2O2 had minimal effect on PON1 activity. In contrast, 
upon the addition of pathophysiological levels of MPO (e.g., 5 nM), 
a dose-dependent inhibition of PON1 catalytic activity was 
observed with increasing levels of H2O2 (Figure 1A). The addition 
of a large molar excess of methionine, a scavenger of hypochlorous 
acid (HOCl) — the major oxidant formed from MPO in the pres-
ence of plasma levels of chloride — blocked the inhibitory effect 
of MPO/H2O2 on PON1, in agreement with HOCl as the reactive 
oxidant responsible for the loss of PON1 catalytic activity. Consis-
tent with this, in a parallel study, HOCl was incrementally added 
to lipoprotein-deficient serum supplemented with HDL and 
PON1 in the absence of MPO. Again, a dose-dependent inhibition 
of PON1 catalytic activity was observed (Figure 1A). Importantly, 
comparisons between the MPO/H2O2/Cl– system (an enzymatic 
source of HOCl) and HOCl at molar-equivalent doses demon-
strated MPO to be a more potent inhibitor of PON1 activity at 
every level of oxidant examined, consistent with MPO binding 
to the HDL-PON1 complex within serum and the reactive HOCl 
formed by MPO having a shorter diffusion distance (and hence, 
less scavenging) before hitting the PON1 target (Figure 1A).
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We next sought to test whether PON1 could influence MPO 
catalytic activity. The addition of PON1 to MPO inhibited per-
oxidase activity by approximately 50% (Figure 1B). The effect of 
PON1 on MPO peroxidase activity was specific, since the replace-
ment of MPO with an alternative heme peroxidase, HRP (but 
the same levels of H2O2 and chromophore substrate), showed 
no effect of PON1 on peroxidase activity (Figure 1B). Interest-
ingly, the addition of HDL to MPO 
resulted in a reproducible, modest 
increase in MPO peroxidase activity; 
however, the addition of PON1 in 
the presence of HDL still resulted in 
a reduction in MPO peroxidase activ-
ity by approximately 50% (Figure 1C). 
To further explore the physiological 
relevance of MPO-PON1 interaction, 
additional studies were performed. 
We previously used isolated human 
neutrophils from normal and MPO- 
deficient subjects to show that neu-
trophil activation in plasma or serum 
is a physiological mechanism for the 
initiation of lipid peroxidation, such 
as at sites of acute inflammation, 
through a mechanism requiring 
MPO (33). We therefore examined 
the impact of PON1 on human neu-
trophil–dependent lipid peroxida-
tion in serum as monitored by stable 
isotope dilution liquid chromatogra-
phy tandem mass spectrometry (LC/
MS/MS) quantification of oxidation 
products of arachidonic (e.g., hydrox-
yeicosatetraenoic acid [HETEs]) and 
linoleic acids (e.g., hydroxyoctadeca-
dienoic acid [HODEs]). As expected, 
the addition of neutrophils from 
normal volunteers (PMNWT) to 
serum failed to promote lipid perox-
idation under basal conditions, but 
did so following neutrophil activa-
tion by the addition of phorbol ester 
agonist (Figure 1D). As an additional 
control to show that the lipid perox-
idation monitored was attributable 
to MPO release from the PMN, par-
allel studies using neutrophils iso-
lated from an MPO-deficient subject 
(PMNMPO–) were performed, demon-
strating no formation of 9-HETE (a 
free radical–specific oxidation prod-
uct of arachidonic acid) following 
the addition of phorbol ester agonist, 
but marked 9-HETE formation upon 
the addition of catalytic levels of 
MPO to activated PMNMPO– (Figure 
1D). The addition of PON1 to serum 
in the presence of quiescent PMNWT 
resulted in no change in 9-HODE or 
9-HETE levels, but markedly atten-
uated the incremental increases in lipid peroxidation products 
formed upon PMNWT stimulation (Figure 1E). In a parallel set of 
studies, the direct impact of PON1 on the extent of MPO-cata-
lyzed formation of multiple distinct molecular species of HETEs 
and HODEs in serum was determined by stable isotope dilution 
LC/MS/MS. Again, the addition of PON1 markedly attenuated 
MPO-dependent initiation of lipid peroxidation and formation of 
Figure 1
MPO and PON1 inhibit each other’s activity in vitro. (A) PON1 (100 μg/ml) was incubated with either 
HOCl or H2O2 and MPO (50 nM) in 50 mM Na[PO4] buffer (pH 7.0) supplemented with isolated human 
HDL (1 mg/ml) and 100 mM NaCl at 37°C for 60 minutes. This was followed by quantification of paraox-
onase activity relative to no oxidant exposures. Also shown are the effects of varying levels of H2O2 
alone (i.e., no MPO added) or with the addition of the HOCl scavenger methionine (Met) (10-fold molar 
excess relative to oxidant) to the MPO/H2O2 system. (B) Effect of PON1 on peroxidase activity by TMB 
assay of either MPO or HRP. (C) Effect by TMB assay of PON1 (650 nM), HDL (650 nM), or both on 
MPO (65 nM) peroxidase activity. (D and E) Human neutrophils isolated from healthy donors (PMNWT) 
or MPO-deficient subjects (PMNMPO–) were incubated at 37°C in 50% serum for 1 hour in the absence 
or presence of phorbol 12-myristrate 13-acetate (PMA) and MPO or PON1, as indicated. Endoge-
nous serum arachidonic acid (AA), linoleic acid (LA), 9-HODE, and 9-HETE were then quantified by 
stable isotope dilution LC/MS/MS as described in Methods. (F) PON1, MPO/H2O2, neither, or both 
were added to 50% serum, incubated at 37°C for 1 hour, and then AA, LA, or the indicated oxidation 
products were quantified as described in Methods. Data shown represent the mean ± SD of triplicate 
determinations. *P < 0.05; **P < 0.001. NA, no additions; oxFA, oxidized fatty acids.
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the various HETEs and HODEs from endogenous lipids in serum 
(Figure 1F). Collectively, these results indicate that within a physi-
ological matrix like plasma or serum, MPO and PON1 can interact 
with one another and modulate each other’s activity.
MPO and PON1 influence each other’s activity in vivo. To further 
extend our observations of the reciprocal inhibitory effects of 
MPO and PON1 on each other’s activity from an in vitro (ex vivo) 
to an in vivo setting, further studies were performed using mice 
genetically engineered to lack (KO) or overexpress (Tg) either 
MPO or PON1. We chose a simple and well-characterized peri-
tonitis model of acute inflammation for these studies, since we 
have previously shown that MPO serves as a major enzymatic 
catalyst for both protein and lipid oxidation within the model 
(31, 34). To examine the impact of PON1 on MPO activity, we 
quantified protein-bound 3-chlorotyrosine (ClTyr), a specific 
molecular fingerprint for MPO-catalyzed protein oxidation (29, 
31), in peritoneal proteins recovered from PON1 KO, WT, and 
PON1 Tg mice following the recruitment of leukocytes to the 
peritoneal cavity with thioglycolate and subsequent activation by 
i.p. injection of yeast cell wall protein carbohydrate components 
(zymosan). Compared with WT, the PON1 KO mice demon-
strated a significant (P = 0.02) approximately 50% increase in 
protein-bound ClTyr content within recovered peritoneal lavage 
fluid proteins (Figure 2A). A dose-dependent effect of increased 
PON1 leading to reduced MPO activity, as monitored by ClTyr 
formation, was further supported by demonstration of an 
approximately 50% reduction (P < 0.01) in peritoneal lavage pro-
tein ClTyr content in PON1 Tg mice relative to the WT controls 
(Figure 2A). Thus, PON1 shows a dose-dependent inhibitory 
effect on the production of the MPO-specific oxidation product, 
ClTyr, in an acute inflammation model.
In a parallel set of studies, we determined the impact of genetic 
alterations in MPO levels on systemic PON1 activity measured 
during inflammation. Here, serum paraoxonase activity was 
measured in a subacute peritonitis model following i.p. zymosan 
injection. In WT mice, chronic inflammation (72 hours) induced 
by the i.p. zymosan resulted in a significant (P < 0.05) 30% reduc-
tion in serum paraoxonase activity (Figure 2B). The initiation of 
peritonitis in the human MPO Tg mouse revealed an even more 
pronounced inhibition in systemic paraoxonase activity (55%, 
P < 0.001), whereas the induction of peritonitis under comparable 
conditions within the MPO KO mouse failed to change systemic 
PON1 activity levels (Figure 2B). Importantly, the examination 
of circulating PON1 concentrations shows similar levels between 
MPO KO and MPO Tg mice (Supplemental Figure 3). Thus, 
changes observed in PON1 activity within serum are consistent 
with the inhibition of catalytic activity (specific activity) of the 
protein via an MPO-dependent process.
Hydrogen deuterium exchange mass spectrometry and mutagenesis 
studies reveal functional interaction sites on APOA1 of HDL and PON1. 
We next sought to identify sites of contact between PON1 and 
APOA1 of reconstituted nascent HDL (nHDL). Hydrogen-deute-
rium exchange mass spectrometry (HDX) is a powerful tool for 
identifying protein-protein interaction sites and was used to iden-
tify the MPO binding site on APOA1 of nHDL (23). We therefore 
used HDX to interrogate the potential site(s) on APOA1 within 
nHDL involved in PON1 interactions. Examination of amide 
proton deuterium incorporation factors in peptic peptides gen-
erated from APOA1 of nHDL in the absence or presence of PON1 
revealed 2 regions of the APOA1 polypeptide chain with a signifi-
cant (>10%) reduction in deuterium incorporation factor in the 
presence of PON1. Multiple overlapping peptic peptides helped 
to define the regions showing a reduction in deuterium exchange 
in the presence of PON1, Leu38-Leu46 (termed P1, located at the 
boundary between the APOA1 N-terminal and helix 1) and Thr202-
Arg215 (termed P2, located at the boundary between helix 8 [7 res-
idues] and helix 9 [7 residues]) (Figure 3, A and B). Examination 
of the locations of these regions on the recently proposed double 
superhelix model of nHDL developed using a combination of con-
trast variation, small-angle neutron scattering, HDX, and chemical 
cross-linking/mass spectrometric studies (37) revealed that P1 and 
P2 are predicted to reside directly opposite to one another on the 2 
antiparallel APOA1 chains (Figure 3C). Moreover, they are in close 
spatial proximity to the site of interaction previously identified 
between MPO and APOA1 in nHDL (APOA1 residues 190–203) 
(23). Of note, the identified peptide regions P1 and P2 of APOA1 
Figure 2
MPO and PON1 inhibit each other’s activity in vivo. (A) PON1 KO, 
WT, or PON1 Tg animals were injected i.p. with normal saline (Bl) or 
thioglycollate broth (T). Twenty-four hours later, peritoneal lavages 
were performed. Where indicated, mice were injected with zymosan (Z) 
24 hours after thioglycollate, and peritoneal lavage was performed 
4 hours later. Chlorotyrosine (ClTyr) content (normalized to the pre-
cursor amino acid tyrosine [Tyr]) in soluble proteins recovered from 
peritoneal lavage was determined by stable isotope dilution LC/MS/MS 
analysis. (B) MPO KO, WT, or MPO Tg animals were injected i.p. with 
normal saline or zymosan (Z). After 72 hours of subacute peritonitis, 
serum was isolated and paraoxonase activity was measured.
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are located directly opposite or adjacent to one another on the 
antiparallel APOA1 chains in every reported HDL model available 
as a Protein Data Bank (PDB) file (37–45).
To examine the functional significance of the APOA1 sequences 
identified as potential contact sites between nHDL and PON1, 
site-directed mutant forms of APOA1 were generated, whereby 
the WT sequences within P1 (L38GKQLNLKL46) and P2 (S201TLSE-
KAK208) were altered, removing potential hydrogen bond and 
ionic interaction sites (P1mut = L38GEALALEL46 and P2mut = 
S201ALAAEAE208) (Figure 3B). Initial control studies using recom-
binant APOA1 mutant forms generated with either the P1mut or 
P2mut sequences revealed that both were functionally active and 
indistinguishable from human APOA1 with respect to overall 
structure as monitored by circular dichroism (Supplemental 
Figure 4A) and ABCA1-dependent efflux activity from cholester-
ol-loaded RAW cells (Supplemental Figure 5A). Similarly, nHDL 
produced using recombinant human APOA1 (WT) versus either 
the P1mut- or P2mut-containing APOA1 forms showed similar 
overall structure (Supplemental Figure 4B) and comparable total 
cholesterol efflux activity with cholesterol-loaded RAW cells (Sup-
plemental Figure 5B). Surface plasmon resonance spectroscopy 
was also performed to evaluate the binding interaction changes 
between PON1 and nHDL produced using recombinant human 
APOA1 (WT) versus either the P1mut- or P2mut-containing APOA1 
mutant forms. KD values of interaction between PON1 and nHDL 
formed with either the P1mut or P2mut recombinant APOA1 forms 
were decreased by 1.6-fold and 2.6-fold, respectively, compared 
with the observed KD values for interaction of PON1 with nHDL 
formed with recombinant human (WT) APOA1 (Supplemental 
Figure 6). We therefore next examined whether P1 or P2 sequences 
in APOA1 were involved in PON1 interactions. Purified PON1 is 
more thermally labile in the absence of HDL and can lose catalytic 
activity with prolonged incubation at 37°C (Figure 4A). However, 
in the presence of either lipid-free APOA1 (Figure 4A, green curve), 
phospholipid vesicles (Figure 4B, purple curve), or nHDL (Figure 
4B, green curve), PON1 activity is both stimulated and stabilized 
over time, consistent with binding to both lipid and protein com-
ponents of reconstituted nHDL. Remarkably, incubation of PON1 
with either of the P1mut- or P2mut-containing recombinant APOA1 
forms or the reconstituted nHDL generated using these mutant 
APOA1 forms showed intermediate capacity to bind, stimulate, 
and stabilize PON1 activity during prolonged incubations at 37°C 
(Figure 4, A and B). The intermediate phenotypes (protection 
from thermal denaturation) observed with nHDL formed using 
the mutant P1 or P2 sequences is consistent with these regions on 
APOA1 serving a functional role in partially supporting the HDL-
PON1 interaction. In another series of experiments, we sought to 
determine whether the strength of the HDL-PON1 binary com-
plex influences MPO activity. Of note, while the binary complex 
formed by PON1 with nHDL that had been formed using WT 
Figure 3
PON1 interaction sites on APOA1 within nHDL 
revealed by HDX MS. (A) Plot indicating the per-
centage of deuterium incorporation of exchange-
able protons within individual peptic peptides of 
APOA1 in nHDL in the absence (black bars) ver-
sus presence (white bars) of PON1. **P < 0.05. 
(B) Plot showing percentage change in deute-
rium incorporation of individual peptic peptides 
of APOA1 in nHDL in the absence or presence 
of PON1. Two regions of APOA1 demonstrate a 
significant reduction in deuterium incorporation in 
the presence or absence of PON1/P1 (L38GKQL-
NLKL46) and P2 (S201TLSEKAK208). Dotted line 
marks the 10% reduction in deuterium incorpora-
tion. (C) Illustration of PON1 interaction domains 
P1 and P2 on APOA1 within the double super-
helix model of nHDL. The two APOA1 molecules 
are aligned in a head-to-tail antiparallel arrange-
ment using a helix 5/helix 5 registry. N-termini are 
shown in dark red/blue, and C-termini are shown 
in light red/blue. PON1 interaction sites on nHDL 
(P1, blue; P2, light red).
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recombinant human APOA1 inhibited MPO activity by approxi-
mately 50%, the PON1 complex formed with nHDL prepared with 
either the P1 or P2 APOA1 mutant demonstrated a reduced ability 
to inhibit MPO activity (Figure 4C).
PON1 Tyr71 is a functionally important site for HDL interaction and a 
target for MPO-catalyzed oxidation in human atherosclerotic plaque. To 
investigate sites on PON1 that may participate in HDL interac-
tions, we generated reconstituted nHDL, incorporating instead 
of cholesterol, a synthetic photoactivatable cholesterol analog 
containing a diazirine moiety at C6 of the sterol, as described in 
Methods (Figure 5A). Following exposure to UV light, the carbene 
diradical formed by N2 elimination from the diazirine has an 
exceedingly short half-life, with diffusion-limited reactivity with 
water (46). Thus, in the presence of an HDL binding partner such 
as PON1, UV light exposure is anticipated to produce a covalent 
adduct only with PON1 residues in close enough spatial prox-
imity to the lipid phase of nHDL to exclude water (Figure 5A). 
Following coincubation of PON1 and nHDL and brief UV light 
exposure, mass spectrometry identified only one residue within 
PON1 that produced a cholestanyl adduct: Tyr71 (Figure 5, A 
and B). Remarkably, separate in vitro studies incubating HDL-
PON1 (1:1, mol/mol) complexes with either the MPO/H2O2/
Cl– system or the MPO/H2O2/NO2– system at low oxidant levels 
(H2O2/APOA1, 10:1, mol/mol) identified in a reproducibly sim-
ilar manner Tyr71 of PON1 as a preferred site of MPO-catalyzed 
oxidative modification, whereby Tyr71 of PON1 was detected as 
either a 3-chlorotyrosine or 3-nitrotyrosine adduct within tryp-
tic peptides by proteomics studies (Supplemental Figures 7, A 
and B). The crystal structure of PON1 was recently reported (47, 
48), and PON1 Tyr71 sits near the putative interfacial region of 
the hypothetical HDL binding domain (Figure 5C), suggesting 
both that Tyr71 of PON1 may support HDL interaction, and that 
MPO-dependent site-specific oxidative modification of PON1 at 
Tyr71 may impair PON1 function in vivo. The potential physio-
logical relevance of PON1 Tyr71 oxidation by MPO was further 
supported by proteomics studies of PON1 recovered from human 
atherosclerotic plaque, in which ClTyr71 was directly visualized 
on PON1 tryptic peptides (Supplemental Figure 8). These results 
demonstrate that within the proinflammatory environment of 
the human atherosclerotic plaque where site-specific oxidation of 
APOA1 through both nitration and chlorination has been shown 
to occur by MPO (6, 23, 35), the HDL-associated protein PON1 
too is oxidized by the heme protein.
In an additional series of studies, we sought to further explore 
the potential functional significance of posttranslational oxidative 
modification of Tyr71 of PON1. Site-directed mutagenesis studies 
of recombinant human PON1 were performed, whereby tyrosine 
was converted to multiple alternative amino acids (alanine, aspar-
tic acid, or lysine). Each of the recombinant mutant PON1 forms 
and recombinant human PON1 were next individually incubated 
with nHDL (1:1, HDL-PON1, mol/mol) at 37°C, and then resid-
ual PON1 catalytic activity was quantified. Functional analyses of 
recombinant human PON1 versus the site-directed mutant forms 
of PON1 (aka Tyr71Ala, Tyr71Asp, or Tyr71Lys) showed that in each 
case, the mutant PON1 form had markedly reduced catalytic 
activity (Figure 5D). Collectively, these studies show that Tyr71 of 
PON1 is both a site-specific target for MPO-catalyzed oxidation in 
human atherosclerotic plaque and a functionally important resi-
due for HDL interaction and preservation of PON1 activity.
HDL-bound PON1 is a selective target for MPO-catalyzed oxidation 
and functional impairment during cardiovascular disease. We next 
sought to further examine the functional and potential clinical 
significance of the interaction between MPO and PON1 within 
the HDL-PON1-MPO ternary complex during cardiovascular dis-
ease. Subjects (n = 26) presenting for diagnostic coronary angiog-
raphy at the time of ACS were consented, and blood was drawn 
for systemic PON1 activity determination and HDL isolation and 
chlorotyrosine content determination. In parallel, age-, sex-, and 
blood pressure–matched healthy nondiabetic control subjects 
(n = 26) were consented and similarly examined. Baseline charac-
Figure 4
Demonstration that APOA1 P1 and P2 regions are functionally important in the HDL-PON1-MPO ternary complex. (A) APOA1 harboring muta-
tions within P1 or P2 region (versus WT) were incubated with PON1 at 37°C for the indicated times, and then paraoxonase activity was deter-
mined. Results were normalized (100%) to PON1 activity measured with no addition (NA) at t = 0. (B) PON1 was incubated with reconstituted 
HDL (rHDL; 100:10:1, OPC/cholesterol/APOA1, mol/mol/mol) using the indicated APOA1 forms (WT versus P1 versus P2 mutants) or small 
unilamellar vesicles (SUV) composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) (16:0, 18:1 phosphatidylcholine [PC]) for the 
indicated times, and then paraoxonase activity was measured. Results were normalized (100%) to PON1 activity measured with no addition at 
t = 0. (C) TMB assay showed the effect of varying levels of the binary complex composed of PON1 and the indicated rHDL (made with WT versus 
P1 versus the P2 APOA1 mutant) on MPO activity. All results represent the mean ± SD from at least 3 independent experiments. In A and B, the 
differences between WT and mutants at the 3-hour point were significant (APOA1 WT versus APOA1 P1, P < 0.05; APOA1 WT versus APOA1 
P2, P < 0.05). In C, the difference between WT and mutants at a molar ratio of rHDL/PON1 to MPO of 20 or greater were significant (rHDL WT 
versus rHDL P1, P < 0.05; rHDL WT versus rHDL P2, P < 0.05).
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teristics and laboratory analyses within the case-control cohort are 
shown in Supplemental Table 1, and Figure 6A shows a scatter plot 
demonstrating the relationship between systemic PON1 activity 
measured within each group and protein-bound 3-chlorotyrosine 
content in the isolated HDL as determined by stable isotope dilu-
tion LC/MS/MS. Of note, examination of the relationship between 
the chlorotyrosine content of HDL and systemic PON1 activity 
showed a significant inverse association within the combined ACS 
plus healthy control cohort (r = –0.54, P < 0.001). Further, despite 
substantial overlap, systemic PON1 activity was significantly 
(P < 0.05) reduced within the ACS cohort compared with the 
healthy controls (Figure 6A), and protein-bound chlorotyrosine 
content of isolated HDL, a specific molecular marker of MPO- 
catalyzed oxidation (29, 31), was also elevated (P < 0.01) within the 
ACS cohort relative to the healthy controls (Figure 6A). The small 
size of this study, however, prevents examination of the impact of 
comorbidities on these associations.
In a final series of studies, we further investigated the oxidative 
inactivation of PON1 during ACS. A separate case-control study 
was performed for more detailed proteomics analyses involving 
an independent cohort of ACS subjects (n = 10) and age-, sex-, and 
blood pressure–matched healthy nondiabetic controls (n = 10). 
Baseline characteristics and laboratory analyses within this inde-
pendent case-control cohort are shown in Supplemental Table 2. 
HDL was isolated from subjects, and then PON1 tryptic peptides 
were examined by proteomics. Methionine residues are highly sus-
ceptible to oxidation and conversion into methionine sulfoxide. 
We therefore quantified site-specific methionine residue oxida-
tion within PON1 recovered from the isolated HDL in both ACS 
and control subjects, as described in Methods. Multiple methion-
ine residues within PON1 were detected, and 3 (Met88, Met55, and 
Met12) were reproducibly observed, permitting quantification of 
both parent (unmodified) and oxidized forms (exemplary spec-
tra shown in Supplemental Figures 9 and 10) within all samples. 
Interestingly, the levels of oxidized Met88 were significantly ele-
vated (P < 0.05) within the PON1 recovered from ACS subjects 
relative to controls (Figure 6B and Supplemental Figure 11), 
indicating that PON1 undergoes site-specific oxidative modifi-
cation during ACS. To assess whether methionine oxidation may 
have functional significance for PON1 activity, we examined the 
impact of methionine sulfoxide reductase incubation with PON1 
that had previously been partially functionally inactivated by 
exposure to the MPO/H2O2/Cl– system. Remarkably, incubation 
of oxidized PON1 with methionine sulfoxide reductase signifi-
cantly reversed a portion of the PON1 inactivation induced by 
MPO-generated oxidants (Figure 6C).
Discussion
MPO release from activated leukocytes, binding to HDL, and 
targeting of APOA1 for oxidative modification and functional 
inactivation of the particle are phenomena recognized to occur 
during inflammation and have been linked to the generation of 
“dysfunctional” forms of HDL (6, 23, 24, 35, 49–51). Moreover, 
a reduction in systemic PON1 activity during cardiovascular dis-
ease in mice and humans has been reported and has been linked 
to the loss of antiinflammatory properties of HDL isolated from 
ACS subjects (7, 15, 19). Finally, a role for MPO in the initiation 
of lipid peroxidation in vivo (33, 34) and a reciprocal association 
between PON1 activity and systemic measures of oxidant stress in 
mice and humans are well documented under a variety of inflam-
matory conditions (15, 19, 20). That these functions of MPO and 
PON1, both HDL-associated proteins, should be mechanistically 
Figure 5
PON1 Tyr71 is a functionally important site 
for HDL interaction and a target for MPO-
catalyzed oxidation in human atherosclerotic 
plaque. (A) Schematic illustration of photo-
cholestanyl-labeled PON1 tyrosyl residue. 
(B) Reconstituted HDL formed using POPC/
photocholesterol/APOA1 (100:10:1) was 
incubated with PON1 and exposed to UV 
light as described in Methods. Proteomics 
studies revealed the photocholestanyl adduct 
of PON1 Tyr71 [Y(ch)] as a site on PON1 
that directly interacts with cholesterol as 
described in Methods. m/z, mass-to-charge 
ratio. (C) PON1 crystal structure with super-
imposed location of Tyr71 (red) and hypothet-
ical HDL binding surface based on hydro-
phobicity analysis. (D) Recombinant human 
WT PON1 versus the indicated PON1 Tyr71 
site–specific mutants were generated, iso-
lated, incubated with HDL, and then paraox-
onase activity was determined as described 
in Methods. Results represent the mean ± SD 
from at least 3 independent experiments.
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linked has not yet been examined. We believe that the present stud-
ies demonstrate for the first time both the reciprocal biochemical 
functional relationship between MPO and PON1 activities as they 
relate to systemic measures of oxidant stress and HDL function 
and a structural basis accounting for the linkage of these phe-
nomena — namely, that MPO, PON1, and HDL can form a ternary 
complex whereupon each member of the complex interacts with 
and functionally impacts the other’s activity in vivo. Thus, the 
present studies show that like APOA1 (6, 23), the HDL-associated 
protein PON1 may be targeted for oxidative modification and 
functional inactivation by MPO in vivo, as observed using both 
animal models of inflammation and in human clinical studies of 
the acute inflammatory condition, ACS.
A model of a hypothetical ternary complex of MPO and PON1 
bound to nHDL is illustrated in Figure 7 and can help to pro-
vide a structural rationale for the observed reciprocal regulatory 
behavior among MPO, PON1, and HDL within the context of the 
present studies and prior reported observations. The model is 
not intended to represent a true all-atom structure, but rather is 
an illustration providing a structural and mechanistic rationale 
upon which a variety of biophysical and functional observations 
can be explained. The model shown is based on the known crystal 
structures of PON1 (48) and MPO (52) and represents a model of 
HDL based on small-angle neutron scattering and HDX studies 
of nHDL (37), prior reported sites of MPO-catalyzed oxidative 
modification to APOA1 in HDL (23, 35, 49, 53), previously iden-
tified MPO-APOA1 interaction sites based on hydrogen/deu-
terium (H/D) exchange and functional studies (23), and newly 
discovered sites of oxidation or interaction among the various 
participants in the ternary complex from the present studies. Of 
note, while the discussions of the ternary complex below are based 
on the double superhelix model of nHDL (37) as the scaffolding 
upon which MPO and PON1 are bound (Figure 7), alternative 
models for the HDL-PON1-MPO ternary complex using either a 
discoidal HDL (e.g., solar flare model) (ref. 43 and Supplemental 
Figure 12) or a spherical HDL model (ref. 44 and Supplemental 
Figure 13) as the lipoprotein scaffolding show similar concep-
tual findings in terms of distance constraints between identified 
contact sites within the complex and provide a rationale for sites 
of MPO-catalyzed oxidation observed on APOA1 and PON1 
in vitro and in vivo. Because the double-belt discoidal model 
of HDL contains a truncated APOA1 (residues 44–243), which 
misses 6 residues from the P1 binding site, it was not included. 
The model of the ternary complex is based on the nonoverlap-
ping but directly adjacent sites on APOA1 of nHDL to which the 
interaction sites with MPO and PON1 map. The close proximity 
of these HDL-associated proteins on the HDL scaffold, coupled 
with the high affinity MPO and PON1 show for one another, 
suggest that there may be some direct interaction between 
PON1 and MPO when they are both associated with HDL, and 
this appears to be at the origin of the mutual activity modula-
tion. This observation is supported by the data in Figure 1C, 
which clearly indicate that MPO activity, when it associates with 
PON1 either alone or on an HDL particle, is about half of its 
activity compared with the absence of PON1.
PON1 is an HDL-associated enzyme under consideration as a 
potential therapeutic for cardiovascular disease. While studies 
in both mice (19, 20) and humans (15) support an antioxidant 
function for the protein, the precise mechanism(s) through which 
PON1 promotes its systemic antiinflammatory and antioxidant 
effects are not well defined. Moreover, systemic PON1 activity lev-
els can vary over a very broad range (orders of magnitude), while 
PON1 mass shows less variation, with PON1 abundance in the 
circulation being approximately one-tenth that of HDL parti-
cles (36). The mechanism(s) contributing to the wide variation 
in systemic PON1 activity observed between subjects are not well 
known, but early in vitro studies established the sensitivity of 
PON1 to chemical oxidants (54). The present studies show that 
under inflammatory conditions, MPO-mediated oxidative inac-
tivation contributes to modulation of PON1 in vivo. It should 
Figure 6
Methionine oxidation plays a role in PON1 activity and stability. (A) 
Inverse correlation between systemic PON1 activity and protein con-
tent of ClTyr-isolated HDL from ACS (black ovals; n = 26) and healthy 
nondiabetic control subjects (white ovals; n = 26) from case-control 
cohort 1 (see Supplemental Table 1). P value shown is for the Spear-
man’s rank correlation between PON1 activity level and HDL ClTyr 
content among both control and ACS subjects. (B) Quantification of 
site-specific methionine oxidation (methionine sulfoxide) within PON1 
recovered from isolated HDL from ACS (n = 10) and healthy nondia-
betic control subjects (n = 10) enrolled in case-control cohort 2 (Sup-
plemental Table 2). Results shown are expressed as the peak ratio of 
peptide harboring the indicated methionine sulfoxide residue or parent 
(methionine-harboring) peptide relative to the reference peptide, as 
described in Methods. (C) Isolated human HDL from a healthy donor 
was incubated with the MPO/H2O2/Cl– system (oxHDL), and then the 
effect of exposure to either methionine sulfoxide reductase (+MSR) or 
vehicle control (–MSR) on PON1 activity was determined as described 
in Methods. PON1 activity is expressed relative to paraoxonase activity 
measured in HDL prior to exposure to the MPO/H2O2/Cl– system. Data 
are the mean ± SD of triplicate determinations.
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be noted that functional polymorphisms can also contribute to 
variations in PON1 activity, but the magnitude of alterations are 
relatively modest compared with the breadth of PON1 activity 
levels observed in the systemic circulation (15, 55).
Despite the interest in PON1 and HDL as potential therapeutic 
agents, the structural basis of the PON1-HDL interface has not 
yet been defined. Our studies show that PON1 binding to HDL is 
important for the maintenance of PON1 activity, with both lipid 
and protein components of HDL supporting PON1 interaction 
(Figure 4). Further, using a combination of novel biophysical 
approaches, coupled with site-directed mutagenesis and subse-
quent functional studies, both Tyr71 of PON1 and the APOA1 
sequences P1 (L38GKQLNLKL46) and P2 (S201TLSEKAK208) were 
identified as critical residues in supporting HDL-PON1 interac-
tion (Figures 3–6). PON1 Tyr71 was unambiguously identified as 
a contact site with the lipid phase of HDL through the forma-
tion of a cholestanyl adduct using a reconstituted nHDL parti-
cle generated with a novel photoactivatable cholesterol analog 
(Figure 5). The carbene diradical formed on the cholesterol ana-
log following UV irradiation reacts at a near-diffusion-limited 
rate with H2O, indicating that the interaction between the HDL 
lipid phase and PON1 Tyr71 is sufficiently tight to exclude water, 
and suggesting that the phenol moiety of Tyr71 extends into the 
lipid phase upon HDL binding (Figure 8). It is remarkable that 
recent crystallographic studies of PON1 in a ligand-bound form 
identify PON1 Tyr71 as a critical residue that undergoes confor-
mational change upon ligand binding and plays an important 
role in a hydrogen bond network near the active site (Figure 8 
and ref. 48). Our studies confirm the functional significance of 
PON1 Tyr71 for HDL interaction through site-directed mutagen-
esis, since multiple PON1 mutants lacking Tyr71 demonstrated 
reduced HDL binding, thermal stability, and enzymatic activity 
(Figures 5 and 6). Finally, the in vivo significance of this residue 
is further suggested both by the demonstration that it is targeted 
for MPO-catalyzed nitration and chlorination in model systems 
under physiological levels of oxidant (Supplemental Figure 7) 
and by the detection of PON1 3-chloroTyr71, a specific posttrans-
lational modification formed by MPO in vivo, in PON1 recovered 
from human atherosclerotic plaque (Supplemental Figure 8). 
Importantly, examination of the crystal structure of PON1 indi-
cates that posttranslational modification of the phenolic ring of 
Tyr71 with a bulky substituent (e.g., NO2, Cl) will also interfere 
sterically with the active site cavity walls and prevent Tyr71 from 
forming a hydrogen bond with PON1 Asp183 (Figure 8), a criti-
cal residue that modulates access to the PON1 active site (48). 
While the site of PON1 interaction with HDL was previously 
unknown, the recent crystal structures reported for both free and 
ligand-bound forms of PON1 suggest a possible lipid interfacial 
binding surface based on predicted hydrophobicity characteris-
tics of the protein (47, 48). It is notable that PON1 Tyr71 is struc-
turally positioned near the hypothesized lipid-binding domain 
within PON1 (Figure 5).
The present studies also help explain, in part, the specificity of 
PON1 for interaction with HDL over alternative hydrophobic sur-
faces and lipoproteins, since specific docking sequences on APOA1 
were also identified, showing functional importance in HDL-
PON1 interaction. HDX mass spectrometric studies revealed that 
2 APOA1 regions (L38-L46 and S201-K208) display substantial reduc-
Figure 7
Structural model of a hypothetical ternary complex of MPO and PON1 
bound to nHDL. Illustration of an HDL-MPO-PON1 ternary complex 
composed of the double superhelix model of nHDL and the crystal 
structures of MPO and PON1 bound to one another with identified pro-
tein-protein interaction sites. The two predominantly α helical APOA1 
chains in nHDL are aligned in a head-to-tail antiparallel arrangement. 
N-termini are shown in dark red/blue, and C-termini are shown in light 
red/blue. Phospholipids in the lipid core of nHDL are depicted in semi-
transparent green. PON1 binding sites on APOA1 shown are P1 (L38-
L46, solid blue) and P2 (S201-K208, solid light red). Adjacent MPO binding 
site on APOA1 (residues A190-L203, filled light blue) is also depicted. 
Site-specific oxidative modifications found in PON1 recovered from iso-
lated HDL from either atherosclerotic lesions or ACS plasma include 
Tyr71 (red) and Met55 and Met88 (both green). Met12 of PON1 is not 
shown because the N terminus (16 amino acids) of PON1 was not 
resolved in the PON1 crystal structure reported. Location of the open-
ings to the two heme pockets on the MPO homodimer are predicted 
to be in close spatial proximity to the site-specific oxidative modifica-
tions reported in APOA1 recovered from human atherosclerotic plaque, 
Tyr166, and Tyr192 (solid black). Also shown are the “solar flare” regions of 
APOA1, presumed LCAT interaction sites (solid yellow).
Downloaded on April 14, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/67478
research article
3824 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 9   September 2013
tions in deuterium incorporation at the amide proton in the pres-
ence versus absence of PON1, suggesting within the nHDL particle 
that APOA1 binding to PON1 in these regions is tight enough to 
partially exclude D2O (Figure 3). It should be noted, however, that 
an alternative explanation for the H/D exchange data might be 
that upon PON1 binding, APOA1 within HDL undergoes con-
formational changes that reduce amide proton exchange rates at 
these residues. Mutagenesis studies, however, were also consistent 
with the findings that these regions on APOA1 play a direct role in 
PON1-HDL interaction, since these studies confirmed that both 
P1 and P2 sequences are functionally important in PON1 binding 
to HDL and in the maintenance of PON1 activity (Figures 3 and 4). 
These APOA1 residues, however, do not appear to be critical for 
either HDL formation or cholesterol efflux function (Supplemen-
tal Figures 4 and 5). Notably, what was found upon examination 
of the anatomic location of the two APOA1 regions (P1 and P2) 
on nHDL that help support binding to PON1 provides a logical 
explanation for why these two apparently distant regions on the 
APOA1 polypeptide chain support PON1 interaction — they are 
predicted to be directly adjacent to one another on the two anti-
parallel APOA1 chains within HDL (Figures 3 and 7, and Supple-
mental Figures 12 and 13).
Perhaps one of the more remarkable findings in the present 
studies is the previously unrecognized reciprocal functional inter-
action between MPO and PON1. In vitro studies with both iso-
lated MPO and PON1 in serum or activated neutrophils from nor-
mal and MPO-deficient subjects demonstrate reciprocal effects 
on PON1 and MPO activity within serum (Figure 1), and studies 
with PON1 KO and Tg mice or MPO KO or Tg mice confirmed 
the dose-dependent reciprocal effects of each protein on the 
other’s enzymatic activity in vivo during inflammation (Figure 2). 
Finally, the H/D exchange studies demonstrate that the site on 
APOA1 supporting PON1 binding is in close spatial proximity to 
the previously identified MPO binding site on APOA1 of nHDL 
(23), and proteomics studies on PON1 reveal that Tyr71, along 
with multiple PON1 methionine residues (e.g., M55 and M88), 
are predicted to be in close spatial proximity to 1 of the 2 heme 
pockets of MPO (Figure 7). Indeed, we hypothesize that the struc-
tural rationale for PON1-dependent inhibition in MPO activity 
observed in vitro, which was approximately 50% of total activity 
(Figure 1), likely arises because PON1 binding to MPO may block 
substrate access to 1 of the 2 heme pocket active sites on the MPO 
homodimer (Figure 7). It should be noted that the precise inter-
action sites on MPO for PON1 binding, however, remain to be 
determined. The protease-resistant nature of MPO, coupled with 
its high degree of glycation, hinders structural elucidation of the 
residue(s) on MPO where it interacts with PON1, even though 
the binding interaction shows a KD in the low nanomolar range 
and is tight enough to permit cross immunoprecipitation studies 
to pull down MPO or PON1 along with APOA1 with antibodies 
against the alternative partners in the ternary complex (Supple-
mental Figures 1 and 2).
Prior reported studies demonstrating the selective enrichment of 
NO2Tyr and ClTyr within APOA1 recovered from serum or within 
human atherosclerotic vessels suggest a possible (patho)physio-
logic association between APOA1 and MPO in vivo. More recent 
in vivo studies involving the infusion of MPO into mice demon-
strated reduced macrophage-to-feces reverse cholesterol transport 
(50), also strongly supporting a possible (patho)physiologic asso-
ciation between APOA1 and MPO in vivo. Additionally, this result 
might also indicate a negative effect of MPO on PON1 activity 
in part through interaction with HDL as a trimeric MPO-PON1-
HDL complex. Since PON1 has been suggested to help promote 
some of the cholesterol efflux activity of HDL (56–58), the pres-
ent demonstrations of MPO-dependent oxidative modification 
and inactivation of PON1 in vitro and in vivo may be considered 
an alternative mechanism for generating a “dysfunctional HDL” 
particle (or perhaps more precisely, a “dysfunctional HDL-asso-
ciated proteome”) during inflammation. It is of interest that a 
recently published study examining systemic MPO activity and 
Figure 8
Role of PON1 Tyr71 in HDL binding and catalysis. (A) Illustration indicat-
ing how Tyr71 of PON1 may interact with the cholesteryl group (orange) 
of nHDL. PON1 crystal structure (PDB ID: 1V04) (purple) is shown 
docking with the lipid phase of nHDL (POPC molecules are shown as 
green lines, with the nitrogen atom of the choline group represented 
by blue spheres), and Tyr71 (red) protrudes into the lipid phase, inter-
acting with cholesterol. (B) Illustration comparing the conformation of 
PON1 Tyr71 in the “closed” and “open” conformations of PON1 recently 
reported by Tawfik and colleagues (48). The presumed “lid” domain 
(K70-K81, cyan) in PON1 that seems to control access to the PON1 
active site was resolved in the PON1 crystal structure with a lactone 
analog bound to the active site (PDB ID: 3SRG; closed conformation) 
only. If Tyr71 is nitrated, the bulky NO2 group interferes sterically with 
some of the residues (H184, F222, F292) (purple) in the active site walls. 
The halide Cl has an even larger van der Waals radius and would show 
similar steric interference.
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various HDL-related activities, including cholesterol efflux activ-
ity, antioxidant function, and PON1 activity, among subjects with 
rheumatoid arthritis noted that higher plasma MPO activity was 
associated with worse HDL functional measures (59). In summary, 
HDL appears to serve as the scaffolding upon which functionally 
related proteins can assemble and interact, serving as a mechanism 
to “fine tune” biological functions. The evidence provided herein 
reveals the existence of an HDL-MPO-PON1 ternary complex in 
which each partner in the complex functions to reciprocally mod-
ulate the other’s activity, influencing oxidant stress and lipid per-
oxidation during inflammation. The demonstration that these 
proteins form a functional ternary complex, the identification of 
key residues supporting these interactions, and the demonstration 
that these residues may be targeted for oxidative modification and 
inactivation during inflammation provide a structural basis that 
may partially help explain many of the observations reported in 
both past and the present studies at the cellular, animal model, 
and human clinical investigation levels. Given the complexity and 
heterogeneity of the associated proteins observed in HDL, a vast 
number of distinct functional clusters of proteins on distinct HDL 
assemblies likely exist (60), further adding to the functional com-
plexities of this multifaceted lipoprotein.
Methods
Materials
L-[13C6]tyrosine and L-[13C9,15N1]tyrosine were purchased from Cambridge 
Isotope Laboratories. RAW264.7 cells were obtained from ATCC. [3H]Cho-
lesterol was obtained from Amersham Biosciences. Human MPO was iso-
lated and characterized as described (29). All other reagents were obtained 
from Sigma-Aldrich unless otherwise specified.
General procedures
Protein content was determined by the Markwell-modified Lowry protein 
assay (61) with BSA as a standard. The concentration of H2O2 was deter-
mined spectrophotometrically (ε240 = 39.4 M–1 •cm–1), and the concentration 
of NaOCl was determined spectrophotometrically (ε292=350 M–1 • cm–1). 
LDL and HDL were isolated by sequential ultracentrifugation (62). The 
plasmid (G3C9) for generating recombinant PON1 was provided by Dan 
S. Tawfik (The Weizmann Institute of Science, Rehovot, Israel) and puri-
fied as described (63). Protein-bound ClTyr was quantified as described 
by stable isotope dilution LC/MS/MS analyses using synthetic 3-Cl-[13C6]
tyrosine and L-[13C9,15N1]tyrosine as internal standards on an ABI SCIEX 
QTRAP 5500 mass spectrometer (23, 31). PON1 activity was measured 
using a paraoxon substrate on an open channel of an Architect ci8200 
platform (Abbott Diagnostics), and the rate of generation of paranitro-
phenol was determined at 405 nm using an extinction coefficient of 17,000 
M–1 •cm–1 (21, 22). Activity was determined in reaction mixtures composed 
of 1.5 mM paraoxon, 10 mM Tris HCl (pH 8.0), 1 M sodium chloride, and 
2 mM calcium chloride at 24°C. Results were expressed as micromoles of 
paranitrophenol produced per minute per milliliter of serum. Peroxidase 
activity was measured spectrophotometrically at 650 nm by using a TMB 
substrate. Cholesterol efflux (ABCA1-dependent and total) activity of 
APOA1 and nHDL were determined as described (23).
Clinical specimens
Two clinical case-control cohorts of ACS subjects were enrolled for these 
studies. The first was comprised of subjects (n = 26) presenting for diagnostic 
coronary angiography at the time of ACS and healthy nondiabetic control 
subjects (n = 26; age-, sex-, and blood pressure–matched) presenting to a pre-
ventive cardiology clinic for risk factor evaluation and recommendations. 
An independent cohort of ACS subjects (n = 10) were enrolled from the Car-
diovascular Center, University Hospital Zurich at the time of presentation, 
along with 10 healthy volunteers (age-, sex-, and blood pressure–matched 
controls) responding to advertisements. HDL particles were isolated by 
buoyant density centrifugation from atherosclerotic lesions found in arterial 
tissues obtained at the time of vascular surgery. All tissues were immediately 
rinsed in ice-cold PBS supplemented with 2 mM diethylenetriaminepen-
taacetic acid (DTPA) and immediately snap frozen in buffer (65 mM sodium 
phosphate [pH 7.4], 2 mM DTPA, and 100 μM butylated hydroxytoluene) 
with liquid N2 and stored under argon at –80°C until analysis.
Mouse models of inflammation
Age- and sex-matched C57BL/6J PON1 KO (19), human PON1 Tg (20) 
(>10 generations backcrossed onto a C57BL/6J background) and C57BL/6J 
WT mice were used for acute peritonitis studies. Animals were injected i.p. 
with 1 ml of 4% thioglycollate broth. Twenty hours after recruitment, the 
mice were injected with zymosan (250 mg/kg) (34). Peritoneal lavage was 
performed 4 hours later with PBS containing 100 μM butylated hydroxy-
toluene and 100 μM DTPA, aliquoted into cryovials, and overlaid with 
argon, immediately flash frozen in liquid nitrogen, and stored at –80°C 
until analysis. Age- and sex-matched C57BL/6J MPO KO (>10 generations 
backcrossed onto C57Blk/6J), C57Blk/6J human MPO Tg mice, and WT 
mice were used for subacute peritonitis studies. Zymosan was suspended 
in sterile PBS to a final concentration of 7 mg/ml and injected i.p. at a final 
dose of 100 mg/kg. Seventy-two hours later, blood was drawn from the 
mice. The control animals received i.p. injections of PBS.
Mass spectrometry of neutrophil- and MPO-generated oxidation 
products of arachidonic acid and linoleic acid
Human PMNs were isolated from whole blood obtained from healthy and 
MPO-deficient subjects as described (33) and used immediately for exper-
iments. PMNs (106/ml) were incubated at 37°C with 50% (v/v) human 
serum under air in phenol red–free HBSS supplemented with 100 μM 
DTPA, activated where indicated in Figure 1D and Figure 1E by adding 
200 nM phorbol myristate acetate (PMA), and maintained in suspen-
sion by gentle mixing every 5 minutes. After 2 hours, the reactions were 
stopped by immersion in an ice/water bath, followed by centrifugation 
at 4°C and the immediate addition of 50 μM butylated hydroxytoluene 
and 300 nM catalase to the supernatant. Lipid peroxidation products 
in the supernatant were then rapidly assayed as described below. Reac-
tions with isolated MPO were performed at 37°C in sodium phosphate 
buffer (20 mM, pH 7.0) supplemented with 100 μM DTPA using 65 nM 
MPO and 100 μM H2O2 final (added over at least 4 aliquots every 15 
minutes). Reactions were terminated as described above for the PMN 
studies. Deuterated internal standard, 12(S)-hydroxy-5,8,10,14-eico-
satetraenoic-5,6,8,9,11,12,14,15-d8 acid (12-HETE-d8; Cayman Chem-
ical Company) was added, lipids were extracted, and both precursors 
(arachidonic and linoleic acids) and oxidized fatty acids were quantified 
with stable isotope dilution LC/MS/MS using established methods on an 
ABI SCIEX API 5000 triple quadrupole mass spectrometer (34).
Human APOA1 isolation and nHDL preparation
Human APOA1 was purified from isolated human HDL, and recombinant 
mutant forms of human APOA1 were prepared, the His tag was removed, 
and the forms were isolated as described (43). Reconstituted nHDL was 
prepared using the modified sodium cholate dialysis method (64) at an 
initial molar ratio of 100:10:1 of POPC/cholesterol/isolated APOA1. HDL 
particles were further purified by gel filtration chromatography using a 
Sephacryl S300 column (GE Healthcare).
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protein per well) was diluted in a reaction mixture containing 10 mM Tris-
HCl (pH 8.0), 1 M sodium chloride and 2 mM calcium chloride. The reac-
tion was initiated at 24°C by the addition of 1.5 mM paraoxon. Data are 
the mean ± SD of triplicate determinations.
Immunoprecipitation of HDL (APOA1), MPO, and PON1 in human plasma. 
Human IgG was depleted from human plasma by a protein A column 
(Pierce) initially to decrease nonspecific binding proteins. Human IgG–
depleted plasma (250 μl) spiked with isolated human MPO (60 μg) and 
isolated human PON1 (60 μg) was precleared again using Pansorbin cells. 
Precleared plasma (40 μl) was used for immunoprecipitation studies with 
the indicated IgGs (mAb anti–human APOA1; G45615M; BIODESIGN 
International); mouse mAb against human MPO (ab51065; Abcam), or 
no antibody as a control. For endogenous PON1 immunoprecipitation, 
2 milliliters of human IgG–depleted plasma spiked with 100 μg MPO was 
precleared with Pansorbin cells. Rabbit mAb anti-PON1 (2835-1; Epitom-
ics) was used to immunoprecipitate PON1.
Surface plasmon resonance. Measurements of apparent dissociation con-
stants between nHDL, MPO, or PON1 were performed using a BIAcore 
2000 SPR Biosensor (Biacore) following the methods of Jin et al. (69) 
with modifications. Briefly, 8,000 resonance units of anti-APOA1 anti-
body (Biodesign) or 2,000 resonance units of MPO were immobilized on 
a CM5 sensor chip. nHDL surfaces were generated by injection of 7 μM 
nHDL over the anti-APOA1 antibody surface. The apparent dissociation 
constants were obtained by fitting background-subtracted SPR binding 
data to the 1:1 binding with a drifting baseline model using BIAevaluation 
software, (version 4.0; Biacore).
Statistics
Statistical significance of differences was determined by a 2-tailed Stu-
dent’s t-test or ANOVA where appropriate. Spearman’s rank correlation 
coefficients were calculated to test the correlation between PON1 activity 
and protein-bound 3-ClTyr levels. P values less than 0.05 were considered 
statistically significant.
Study approval
All participants gave written informed consent, and the IRB of the Cleve-
land Clinic Foundation approved the study protocol. Clinical investiga-
tions were conducted in accordance with the Declaration of Helsinki prin-
ciples. All animal studies were performed using approved protocols from 
the Animal Research Committee of the Cleveland Clinic.
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Synthesis and use of photocholesterol to label PON1 residues
Photocholesterol was synthesized by conversion of 6-keto-5α-cholestan-
3β-ol (Sigma-Aldrich) to 6-azi-5α-cholestan-3β-ol (65), and purity was 
established by both NMR and mass spectrometric analyses. nHDL contain-
ing the photocholesterol probe was prepared as above, but included photo-
cholesterol instead of cholesterol. Photocholesterol containing nHDL was 
maintained under a foil wrapper in brown glass vials until use. Photolysis 
was performed on the photo-HDL-PON1 complexes (molar ratio of 1:1) at 
room temperature in the dark using a UV lamp at 350 nm. After delipida-
tion of the photo-HDL-PON1 complex, photolabeled proteins were sub-
jected to LC/MS/MS analysis using an LTQ-MS system (Thermo Fisher 
Scientific) for the identification of photocholesterol-labeled peptides.
Proteomics analyses of PON1
Sample preparations and LC-ESI-MS/MS. HDL was precipitated by chloro-
form/methanol (2:1 vol/vol), reduced with DTT, alkylated with iodoacet-
amide, and digested with sequencing grade trypsin (Promega). Peptides 
were analyzed on a hybrid LTQ Orbitrap mass spectrometer (Thermo 
Fisher Scientific) interfaced with a nanoelectrospray ion source. Peptides 
were separated on a reverse-phase column using an acetonitrile and water 
solvent system containing 0.2% formic acid with a flow rate of 200 nl/
minute. Up to 5 data-dependent MS2 spectra of the most abundant dou-
bly or triply charged precursor signals were acquired in the linear ion trap 
using collision-induced dissociation. Peak lists were generated using either 
Bioworks Browser 3.2 (Thermo Fisher Scientific) or Mascot Distiller soft-
ware 2.3.2 (Matrix Science). The resulting Unified Search Files (*.srf) were 
searched against the UniProt FASTA of APOA1 (P02647 [25-267]), while 
Mascot Generic Files (*.mgf) were searched using the Mascot server v2.2 
(1) against a human protein database downloaded from the European Bio-
informatic Institute (EBI) (release date: 19/01/2010). Only strictly tryptic 
peptides (66) with a maximum of 1 missed cleavage site were allowed in 
the database searches. Monoisotopic precursor ions were searched with a 
tolerance of 6 ppm, with 0.5 Da for the fragment ions in the data obtained 
from the hybrid LTQ Orbitrap mass spectrometer. The signal tolerance for 
the ion trap mass spectrometer was 1.0 Da for the precursor ion and 0.5 Da 
for the fragment ions. Unidentified fragment ions in all fragmentation 
spectra were manually validated using Protein Prospector (University of 
California) (67, 68). H/D exchange and tandem mass spectrometric studies 
were performed as described previously (23, 43).
Quantification of oxidized paraoxonase peptides. Two PON1 peptides (IFFY-
DSENPPASEVLR; VVAEGFDFANGINISPDGK) that were not modified 
and readily observable were selected as reference peptides, and extracted 
ion chromatograms were obtained from these peptides. Extracted ion 
chromatograms were also obtained from modified peptides containing 
methionine oxidation and their corresponding unmodified parent pep-
tides. The chromatographic peak area ratio was calculated as the peak 
area of oxidized or parent unmodified peptide divided by the peak area of 
the reference peptide.
Effect of methionine sulfoxide reductase on PON1 activity. HDL was incubated 
with the MPO/H2O2/Cl system at a molar ratio of H2O2/APOA1 (50:1, 
mol/mol) at 37°C for 1 hour in 10 mM sodium phosphate buffer (pH 7.4) 
containing 100 M DTPA. For the MPO-H2O2Cl system, the reaction mix-
ture was supplemented with 50 nM MPO, 100 mM NaCl, and 250 μM 
H2O2. Oxidation was terminated by the addition of 5 mM methionine. For 
the reduction reaction, oxidized HDL (5 μM APOA1) was incubated with 
1 μM methionine sulfoxide reductase (MsrA) and 1 μM MsrB (both from 
Jena Bioscience) for 2 hours at 37°C in Tris-HCl buffer (25 mM, pH 7.4) 
containing 15 mM dithiothreitol. Paraoxonase activity for the MsrA study 
was measured by UV spectrophotometry in a 96-well plate format (Nun-
clon Surface) using paraoxon (Sigma-Aldrich) as a substrate. HDL (100 μg 
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